logo-loader
ANGLE PLC

ANGLE on track to complete key Parsortix study in current quarter

ANGLE is looking to become the first company to receive FDA clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis

parsortix
Parsortix analyses blood for signs of cancer

ANGLE PLC (LON:AGL) expects to complete the clinical study of its Parsortix cancer detection technology by the end of March this year.

So far, 369 of the required 400 patients – 200 with breast cancer and 200 healthy – have been enrolled in the study.

READ: ANGLE device has lymph node potential, says German research team

ANGLE is looking to become the first company to receive Food and Drug Administration clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis.

Given the “continued progress” to date, ANGLE remains confident in wrapping up the trial and data analysis in the current quarter.

“The first half of the year has been one of continued progress by ANGLE and we look forward to completing our FDA clinical and analytical studies in metastatic breast cancer in the US in Q1 2019 with only 31 more subjects to recruit,” said chairman Garth Selvey.

Ovarian cancer test progressing well

In the same update, the AIM company confirmed that the pre-study of an ovarian cancer test, which combines Parsortix with its HyCEAD Ziplex analysis platform, is due to start in the current quarter, subject to ethics approval.

“Significant progress has also been achieved in the optimisation of our recently acquired HyCEAD Ziplex platform for downstream analysis in preparation for our ovarian cancer clinical verification study,” added chairman Selvey.

Healthy cash balance

In the six months ended 31 October, revenue and grant income totalled £0.4mln (H1 17/18: £0.2mln).

Loss from continuing operations widened to £4.2mln (H1 17/18: £3.4mln) reflecting planned investment.

Following a £12.7mln fundraise back in June, ANGLE ended the half with £14.9mln in the bank (April 2018: £7.6mln).

Quick facts: ANGLE PLC

Price: £0.71

Market: AIM
Market Cap: £122.66 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Endorsement for Angle's liquid biopsy system Parsortix

Top stories from the Proactive Investors UK newsroom. Angle (LON:AGL) has received an endorsement for its liquid biopsy system Parsortix from European cancer centre UKE, which says it has potential as a biomarker to test for lung cancer. Security group Westminster (LON:WSG) has signed...

on 21/6/19

2 min read